COMPAR-P: Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Prostate

Sponsor
Azienda Ospedaliera Universitaria Integrata Verona (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05766163
Collaborator
(none)
150
1
3
18
8.3

Study Details

Study Description

Brief Summary

The object of this exploratory clinical trial is to evaluate post-operative complications in a population that underwent Robotic Assisted Radical Prostatectomy (RARP) made with multiple platforms:

  • DaVinci;

  • Hugo;

  • Versius.

The questions it aims to answer are:
  • Does the estimation of the post-operative complications suggest something?

  • Are differences (intra-operative, post-operative, oncological, functional, technical, and economic) among the three intervention approaches observable?

Participants will be invited to fill out questionnaires and join one of these three groups:
  1. surgery with the daVinci platform;

  2. surgery with the Hugo platform;

  3. surgery with the Versius platform.

Condition or Disease Intervention/Treatment Phase
  • Device: DaVinci RARP
  • Device: Hugo RARP
  • Device: Versius RARP
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Comparative Evaluation of New Surgical Robotic Platforms for the Radical Prostatectomy Procedure
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: DaVinci system

Robot-assisted radical prostatectomy is carried out through daVinci platform.

Device: DaVinci RARP
Assisted-robotic radical prostatectomy.
Other Names:
  • DaVinci® Surgical System
  • Experimental: Hugo system

    Robot-assisted radical prostatectomy is carried out through Hugo platform.

    Device: Hugo RARP
    Assisted-robotic radical prostatectomy.
    Other Names:
  • Hugo™ RAS System
  • Experimental: Versius system

    Robot-assisted radical prostatectomy is carried out through Versius platform.

    Device: Versius RARP
    Assisted-robotic radical prostatectomy.
    Other Names:
  • Versius® Robotic Surgery System
  • Outcome Measures

    Primary Outcome Measures

    1. Number of participants with postoperative complications [Over the 4 days post surgery]

      Overall postoperative complications (% score >0) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication

    2. Number of participants with moderate to major postoperative complications [Over the 4 days post surgery]

      Moderate to major complications (% score >=2) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication

    3. Number of participants with major postoperative complications [Over the 4 days post surgery]

      Major complications (% score >=3) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication

    Secondary Outcome Measures

    1. Estimated Blood Loss [Intraoperative]

      Volume

    2. Overall duration of the surgery [Intraoperative]

      Minutes

    3. Anesthesia, Lymphadenectomy, Prostatectomy [Entrance of patient into operating room until completion of surgery]

      Minutes

    4. Number and type of intraoperative complications [Intraoperative]

      Note

    5. Postoperative hospitalization [From the surgery day up to 10 days postoperative]

      Days of recovery until the date of release

    6. Postoperative pain [1-4 days postoperative]

      Numerical Rating Scale (NRS) 0-10 scale for the self-reported rate of pain: zero meaning "no pain" and 10 meaning "the worst pain imaginable"

    7. Prostate Specific Antigen (PSA) [1 month follow-up]

      PSA test

    8. Positive Surgical Margin [Up to 2 weeks postoperative (during histological analysis)]

      Rate at histological examination

    9. Lymph nodes resection [Intraoperative]

      Number of lymph nodes removed

    10. Urinary, sexual, and intestinal function assessment [Preoperative and follow-up (1, 3 and 6 months)]

      University of California, Los Angeles (UCLA) Prostate Cancer Index (PCI) questionnaire Domains: Urinary function (5 items) Urinary bother (1 item) Sexual function (8 items) Sexual bother (1 item) Bowel function (4 items) Bowel bother (1 item) Response options: 3- to 6-point Likert scales. The higher the score, the better the outcome

    11. Quality of Life Evaluation [Preoperative and follow-up at 1, 3 and 6 months]

      Short Form Health Survey (SF-36) 36 questions (8 domains) for self-reported measure of health. Domain score from 0 to 100: the higher the score, the more favorable the state of health

    12. Time taken for platform-related technical steps [From the room setting, through surgical procedure until postoperative room restoration for each of expected 150 surgeries (through study completion: an average of 1 year)]

      Set up of operating table, Electric connections, Draping, Undraping, Docking, Undocking, Cleaning: time in minutes

    13. Possible malfunction of the platform [Intraoperative]

      Note

    14. Procedure-related costs [From surgical procedure to the end of follow-up period (6 months)]

      Estimate

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age > 18 and < 90 years;

    • Organ-localized prostate cancer with a surgical indication of radical prostatectomy;

    • Informed consent provided.

    Exclusion Criteria:
    • Age < 18 and > 90 years;

    • Contraindication to radical prostatectomy procedure;

    • Non-organ confined prostate cancer;

    • Refusal to participate.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Urology Unit, AOUI Verona Verona Italy 37126

    Sponsors and Collaborators

    • Azienda Ospedaliera Universitaria Integrata Verona

    Investigators

    • Principal Investigator: Alessandro AA Antonelli, Azienda Ospedaliera Universitaria Integrata Verona

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Alessandro Antonelli, MD, Prof, Director of Urology Unit, Azienda Ospedaliera Universitaria Integrata Verona
    ClinicalTrials.gov Identifier:
    NCT05766163
    Other Study ID Numbers:
    • COMPAR-P
    First Posted:
    Mar 13, 2023
    Last Update Posted:
    Mar 13, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Alessandro Antonelli, MD, Prof, Director of Urology Unit, Azienda Ospedaliera Universitaria Integrata Verona
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 13, 2023